Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review
- Author:
Kai ZHANG
1
;
Jeremy TEOH
;
Gang ZHU
;
Chi-Fai NG
;
Michel SUBERVILLE
;
Pilar LAGUNA
;
Jean de la ROSETTE
Author Information
- Publication Type:Original Article
- From:The World Journal of Men's Health 2025;43(2):321-332
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Irreversible electroporation (IRE) is a promising alternative treatment for low-intermediate-risk localized prostate cancer. In this systematic review we aim to evaluate the safety profile and functional and oncological outcomes of this new technique.
Materials and Methods:A systematic review of the literature was performed on PubMed, EMBASE, and Scopus up to 24 August 2023. Nineteen studies were analyzed, including 12 prospective studies and 7 retrospective studies. A total of 1,452 patients underwent IRE as the sole primary treatment modality.
Results:The in-field clinically significant prostate cancer rate was reported between 0%–15.6% in the repeat biopsy. The retreatment rate was reported from 8% to 36.6%. The 3 years failure-free survival was presented between 90%–96.8%. The post-operative pad-free rate ranged between 96.7%–100%. Greater heterogeneity exists considering the change in erectile function. The most common reported complications were urinary tract infection and hematuria. Major complications were rare.
Conclusions:These results underline that IRE achieves favorable oncological control with an excellent safety profile, in the meantime preserving patients’ urinary and erectile function
